Provided by Tiger Trade Technology Pte. Ltd.

Rocket Pharmaceuticals, Inc.

3.48
+0.07002.05%
Post-market: 3.530.0500+1.44%19:30 EDT
Volume:2.64M
Turnover:9.21M
Market Cap:382.02M
PE:-20.47
High:3.57
Open:3.57
Low:3.40
Close:3.41
52wk High:5.45
52wk Low:2.53
Shares:109.77M
Float Shares:84.96M
Volume Ratio:1.53
T/O Rate:3.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1700
EPS(LYR):-2.0100
ROE:-4.77%
ROA:-28.42%
PB:1.04
PE(LYR):-1.73

Loading ...

Rocket Pharma sells priority review voucher for $180 million

Reuters
·
Apr 28

Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher

THOMSON REUTERS
·
Apr 28

Rocket Pharmaceuticals Inc - Cash Runway Extended Into Second Quarter of 2028

THOMSON REUTERS
·
Apr 28

LifeSci Capital Sticks to Their Buy Rating for Rocket Pharmaceuticals (RCKT)

TIPRANKS
·
Apr 20

Rocket Pharma Advances Cardiac Gene Therapy Trial, Keeping RCKT on Investors’ Radar

TIPRANKS
·
Apr 17

US FDA's accelerated approval for drugs needs more transparency, says research firm

Reuters
·
Apr 16

Analysts Conflicted on These Healthcare Names: Rocket Pharmaceuticals (RCKT), Merit Medical Systems (MMSI) and Vaxcyte (PCVX)

TIPRANKS
·
Apr 15

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Rocket Pharmaceuticals (RCKT) and Moderna (MRNA)

TIPRANKS
·
Apr 06

BRIEF-FDA Issuance Of A Priority Review Voucher To The Sponsor Of A Rare Pediatric Disease Product Application- Federal Register Website

Reuters
·
Apr 01

FDA: Issuance of a Priority Review Voucher to the Sponsor of a Rare Pediatric Disease Product Application- Federal Register Website

THOMSON REUTERS
·
Apr 01

Rocket Pharmaceuticals Is Maintained at Buy by B of A Securities

Dow Jones
·
Mar 30

Assessing Rocket Pharmaceuticals (RCKT) Valuation After Accelerated FDA Approval Of KRESLADI

Simply Wall St.
·
Mar 30

Rocket Pharmaceuticals price target raised to $11 from $9 at Leerink

TIPRANKS
·
Mar 28

Rocket Pharmaceuticals Is Maintained at Buy by Chardan Capital

Dow Jones
·
Mar 28

PRV reception could net Rocket $100M-$200M, says LifeSci Capital

TIPRANKS
·
Mar 28

Rocket Pharmaceuticals stock weakness unwarranted, says Wedbush

TIPRANKS
·
Mar 28

BUZZ-U.S. STOCKS ON THE MOVE-Entergy, IDEX Corp, Quanta Services

Reuters
·
Mar 27

Rocket Pharmaceuticals Shares Reverse Premarket Gains, Last Down 10%

THOMSON REUTERS
·
Mar 27

Rocket Pharma Exec Says Co in Active Discussions and Engaging With External Parties Regarding the Sale of the Priority Review Voucher

THOMSON REUTERS
·
Mar 27

Rocket Pharma Exec Says Co Has Been Engaging With Payers to Ensure Reimbursement Ahead of Launch - Conf Call

THOMSON REUTERS
·
Mar 27